This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Burtrum, D. Articles by Ludwig, D. L. Search for Related Content PubMed PubMed Citation Articles by Burtrum, D. Articles by Ludwig, D. L.

A Fully Human Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Blocks Ligand-Dependent Signaling and Inhibits Human Tumor Growth in Vivo

ImClone Systems Incorporated, New York, New York

The insulin-like growth factor I receptor (IGF-IR) is overexpressed in many diverse tumor types and is a critical signaling molecule for tumor cell proliferation and survival. Therapeutic strategies targeting the IGF-IR may therefore be effective broad-spectrum anticancer agents. Through screening of a Fab phage display library, we have generated a fully human antibody (A12) that binds to the IGF-IR with high affinity (4.11 x 10^-11 M) and inhibits ligand binding with an IC₅₀ of 0.6–1 nM. Antibody-mediated blockade of ligand binding to the IGF-IR inhibited downstream signaling of the two major insulin-like growth factor (IGF) pathways, mitogen-activated protein kinase and phosphatidylinositol 3'-kinase/Akt, in MCF7 human breast cancer cells. As a result, the mitogenic and proliferative potential of IGF-I and IGF-II were significantly reduced. A12 did not block insulin binding to the insulin receptor but could block binding to atypical IGF-IR in MCF7 cells. In addition, A12 was shown to induce IGF-IR internalization and degradation on specific binding to tumor cells, resulting in a significant reduction in cell surface receptor density. In xenograft tumor models in vivo, IGF-IR blockade by A12 was shown to occur rapidly, resulting in significant growth inhibition of breast, renal, and pancreatic tumors. Histological analysis of tumor sections demonstrated a marked increase in apoptotic tumor cells in antibody-treated animals. These results demonstrate that A12 possesses strong antitumor activity in vitro and in vivo and may therefore be an effective therapeutic candidate for the treatment of cancers that are dependent on IGF-IR signaling for growth and survival.

This article has been cited by other articles:

				U. K. Misra, Y. Mowery, S. Kaczowka, and S. V. Pizzo Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis Mol. Cancer Ther., May 1, 2009; 8(5): 1350 - 1362. [Abstract] [Full Text] [PDF]

				A. Doern, X. Cao, A. Sereno, C. L. Reyes, A. Altshuler, F. Huang, C. Hession, A. Flavier, M. Favis, H. Tran, et al. Characterization of Inhibitory Anti-insulin-like Growth Factor Receptor Antibodies with Different Epitope Specificity and Ligand-blocking Properties: IMPLICATIONS FOR MECHANISM OF ACTION IN VIVO J. Biol. Chem., April 10, 2009; 284(15): 10254 - 10267. [Abstract] [Full Text] [PDF]

				J.-E. Choi, S.-s. Lee, D. A. Sunde, I. Huizar, K. L. Haugk, V. J. Thannickal, R. Vittal, S. R. Plymate, and L. M. Schnapp Insulin-like Growth Factor-I Receptor Blockade Improves Outcome in Mouse Model of Lung Injury Am. J. Respir. Crit. Care Med., February 1, 2009; 179(3): 212 - 219. [Abstract] [Full Text] [PDF]

				F. M. Barlaskar, A. C. Spalding, J. H. Heaton, R. Kuick, A. C. Kim, D. G. Thomas, T. J. Giordano, E. Ben-Josef, and G. D. Hammer Preclinical Targeting of the Type I Insulin-Like Growth Factor Receptor in Adrenocortical Carcinoma J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 204 - 212. [Abstract] [Full Text] [PDF]

				B. C. Litzenburger, H.-J. Kim, I. Kuiatse, J. M. Carboni, R. M. Attar, M. M. Gottardis, C. R. Fairchild, and A. V. Lee BMS-536924 Reverses IGF-IR-Induced Transformation of Mammary Epithelial Cells and Causes Growth Inhibition and Polarization of MCF7 Cells Clin. Cancer Res., January 1, 2009; 15(1): 226 - 237. [Abstract] [Full Text] [PDF]

				L. Cao, Y. Yu, I. Darko, D. Currier, L. H. Mayeenuddin, X. Wan, C. Khanna, and L. J. Helman Addiction to Elevated Insulin-like Growth Factor I Receptor and Initial Modulation of the AKT Pathway Define the Responsiveness of Rhabdomyosarcoma to the Targeting Antibody Cancer Res., October 1, 2008; 68(19): 8039 - 8048. [Abstract] [Full Text] [PDF]

				J. Rodon, V. DeSantos, R. J. Ferry Jr., and R. Kurzrock Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials Mol. Cancer Ther., September 1, 2008; 7(9): 2575 - 2588. [Abstract] [Full Text] [PDF]

				Y. Shang, Y. Mao, J. Batson, S. J. Scales, G. Phillips, M. R. Lackner, K. Totpal, S. Williams, J. Yang, Z. Tang, et al. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake Mol. Cancer Ther., September 1, 2008; 7(9): 2599 - 2608. [Abstract] [Full Text] [PDF]

				M. Q. Lacy, M. Alsina, R. Fonseca, M. L. Paccagnella, C. L. Melvin, D. Yin, A. Sharma, M. Enriquez Sarano, M. Pollak, S. Jagannath, et al. Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma J. Clin. Oncol., July 1, 2008; 26(19): 3196 - 3203. [Abstract] [Full Text] [PDF]

				W. Piao, Y. Wang, Y. Adachi, H. Yamamoto, R. Li, A. Imsumran, H. Li, T. Maehata, M. Ii, Y. Arimura, et al. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas Mol. Cancer Ther., June 1, 2008; 7(6): 1483 - 1493. [Abstract] [Full Text] [PDF]

				D. Sachdev and D. Yee Disrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 39 - 58. [Abstract] [Full Text] [PDF]

				Y. Kusada, T. Morizono, A. Matsumoto-Takasaki, K. Sakai, S. Sato, H. Asanuma, A. Takayanagi, and Y. Fujita-Yamaguchi Construction and Characterization of Single-chain Antibodies Against Human Insulin-like Growth Factor-I Receptor from Hybridomas Producing 1H7 or 3B7 Monoclonal Antibody J. Biochem., January 1, 2008; 143(1): 9 - 19. [Abstract] [Full Text] [PDF]

				P. D. Ryan and P. E. Goss The Emerging Role of the Insulin-Like Growth Factor Pathway as a Therapeutic Target in Cancer Oncologist, January 1, 2008; 13(1): 16 - 24. [Abstract] [Full Text] [PDF]

				L. S. Quinn, B. G. Anderson, and S. R. Plymate Muscle-specific overexpression of the type 1 IGF receptor results in myoblast-independent muscle hypertrophy via PI3K, and not calcineurin, signaling Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1538 - E1551. [Abstract] [Full Text] [PDF]

				L. Wang, T. C. Schulz, E. S. Sherrer, D. S. Dauphin, S. Shin, A. M. Nelson, C. B. Ware, M. Zhan, C.-Z. Song, X. Chen, et al. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling Blood, December 1, 2007; 110(12): 4111 - 4119. [Abstract] [Full Text] [PDF]

				S. R. Plymate, K. Haugk, I. Coleman, L. Woodke, R. Vessella, P. Nelson, R. B. Montgomery, D. L. Ludwig, and J. D. Wu An Antibody Targeting the Type I Insulin-like Growth Factor Receptor Enhances the Castration-Induced Response in Androgen-Dependent Prostate Cancer Clin. Cancer Res., November 1, 2007; 13(21): 6429 - 6439. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky, H. Youssoufian, J. R. Tonra, P. Solomon, D. Burtrum, and D. L. Ludwig IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Clin. Cancer Res., September 15, 2007; 13(18): 5549s - 5555s. [Abstract] [Full Text] [PDF]

				C. J. Barnes, K. Ohshiro, S. K. Rayala, A. K. El-Naggar, and R. Kumar Insulin-like Growth Factor Receptor as a Therapeutic Target in Head and Neck Cancer Clin. Cancer Res., July 15, 2007; 13(14): 4291 - 4299. [Abstract] [Full Text] [PDF]

				L. Conti, G. Regis, A. Longo, P. Bernabei, R. Chiarle, M. Giovarelli, and F. Novelli In the absence of IGF-1 signaling, IFN-{gamma} suppresses human malignant T-cell growth Blood, March 15, 2007; 109(6): 2496 - 2504. [Abstract] [Full Text] [PDF]

				H. D. Sun, M. Malabunga, J. R. Tonra, R. DiRenzo, F. E. Carrick, H. Zheng, H.-R. Berthoud, O. P. McGuinness, J. Shen, P. Bohlen, et al. Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E964 - E976. [Abstract] [Full Text] [PDF]

				G. W. Allen, C. Saba, E. A. Armstrong, S.-M. Huang, S. Benavente, D. L. Ludwig, D. J. Hicklin, and P. M. Harari Insulin-like Growth Factor-I Receptor Signaling Blockade Combined with Radiation Cancer Res., February 1, 2007; 67(3): 1155 - 1162. [Abstract] [Full Text] [PDF]

				D. Sachdev and D. Yee Disrupting insulin-like growth factor signaling as a potential cancer therapy Mol. Cancer Ther., January 1, 2007; 6(1): 1 - 12. [Abstract] [Full Text] [PDF]

				J. D. Wu, K. Haugk, I. Coleman, L. Woodke, R. Vessella, P. Nelson, R. B. Montgomery, D. L. Ludwig, and S. R. Plymate Combined In vivo Effect of A12, a Type 1 Insulin-Like Growth Factor Receptor Antibody, and Docetaxel against Prostate Cancer Tumors. Clin. Cancer Res., October 15, 2006; 12(20): 6153 - 6160. [Abstract] [Full Text] [PDF]

				J. M. O'Toole, K. E. Rabenau, K. Burns, D. Lu, V. Mangalampalli, P. Balderes, N. Covino, R. Bassi, M. Prewett, K. J. Gottfredsen, et al. Therapeutic Implications of a Human Neutralizing Antibody to the Macrophage-Stimulating Protein Receptor Tyrosine Kinase (RON), a c-MET Family Member. Cancer Res., September 15, 2006; 66(18): 9162 - 9170. [Abstract] [Full Text] [PDF]

				G. Descamps, S. Wuilleme-Toumi, V. Trichet, C. Venot, L. Debussche, T. Hercend, M. Collette, N. Robillard, R. Bataille, and M. Amiot CD45neg but Not CD45pos Human Myeloma Cells Are Sensitive to the Inhibition of IGF-1 Signaling by a Murine Anti-IGF-1R Monoclonal Antibody, mAVE1642 J. Immunol., September 15, 2006; 177(6): 4218 - 4223. [Abstract] [Full Text] [PDF]

				V. L. T. Ballard, J. M. Holm, and J. M. Edelberg Quantitative PCR-based approach for rapid phage display analysis: a foundation for high throughput vascular proteomic profiling Physiol Genomics, September 14, 2006; 26(3): 202 - 208. [Abstract] [Full Text] [PDF]

				Z. Wang, G. Chakravarty, S. Kim, Y. D. Yazici, M. N. Younes, S. A. Jasser, A. A. Santillan, C. D. Bucana, A. K. El-Naggar, and J. N. Myers Growth-Inhibitory Effects of Human Anti-Insulin-Like Growth Factor-I Receptor Antibody (A12) in an Orthotopic Nude Mouse Model of Anaplastic Thyroid Carcinoma Clin. Cancer Res., August 1, 2006; 12(15): 4755 - 4765. [Abstract] [Full Text] [PDF]

				L. M. Schnapp, S. Donohoe, J. Chen, D. A. Sunde, P. M. Kelly, J. Ruzinski, T. Martin, and D. R. Goodlett Mining the Acute Respiratory Distress Syndrome Proteome: Identification of the Insulin-Like Growth Factor (IGF)/IGF-Binding Protein-3 Pathway in Acute Lung Injury Am. J. Pathol., July 1, 2006; 169(1): 86 - 95. [Abstract] [Full Text] [PDF]

				S. L. Spence, A. L. Shaffer, L. M. Staudt, S. Amde, S. Manney, C. Terry, K. Weisz, and P. Nissley Transformation of Late Passage Insulin-Like Growth Factor-I Receptor Null Mouse Embryo Fibroblasts by SV40 T Antigen. Cancer Res., April 15, 2006; 66(8): 4233 - 4239. [Abstract] [Full Text] [PDF]

				S. D. Oldroyd, Y. Miyamoto, A. Moir, T. S. Johnson, A. M. El Nahas, and J. L. Haylor An IGF-I antagonist does not inhibit renal fibrosis in the rat following subtotal nephrectomy Am J Physiol Renal Physiol, March 1, 2006; 290(3): F695 - F702. [Abstract] [Full Text] [PDF]

				D. Sachdev, R. Singh, Y. Fujita-Yamaguchi, and D. Yee Down-regulation of Insulin Receptor by Antibodies against the Type I Insulin-Like Growth Factor Receptor: Implications for Anti-Insulin-Like Growth Factor Therapy in Breast Cancer Cancer Res., February 15, 2006; 66(4): 2391 - 2402. [Abstract] [Full Text] [PDF]

				K. E. O'Reilly, F. Rojo, Q.-B. She, D. Solit, G. B. Mills, D. Smith, H. Lane, F. Hofmann, D. J. Hicklin, D. L. Ludwig, et al. mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt Cancer Res., February 1, 2006; 66(3): 1500 - 1508. [Abstract] [Full Text] [PDF]

				E. Menu, H. Jernberg-Wiklund, T. Stromberg, H. De Raeve, L. Girnita, O. Larsson, M. Axelson, K. Asosingh, K. Nilsson, B. Van Camp, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model Blood, January 15, 2006; 107(2): 655 - 660. [Abstract] [Full Text] [PDF]

				A. Al-Zahrani, M. S. Sandhu, R. N. Luben, D. Thompson, C. Baynes, K. A. Pooley, C. Luccarini, H. Munday, B. Perkins, P. Smith, et al. IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer Hum. Mol. Genet., January 1, 2006; 15(1): 1 - 10. [Abstract] [Full Text] [PDF]

				Y. Feng, Z. Zhu, X. Xiao, V. Choudhry, J. C. Barrett, and D. S. Dimitrov Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function Mol. Cancer Ther., January 1, 2006; 5(1): 114 - 120. [Abstract] [Full Text] [PDF]

				B. S. Miller and D. Yee Type I Insulin-like Growth Factor Receptor as a Therapeutic Target in Cancer Cancer Res., November 15, 2005; 65(22): 10123 - 10127. [Abstract] [Full Text] [PDF]

				Y. Wang, J. Hailey, D. Williams, Y. Wang, P. Lipari, M. Malkowski, X. Wang, L. Xie, G. Li, D. Saha, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody Mol. Cancer Ther., August 1, 2005; 4(8): 1214 - 1221. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Second World Congress on the Insulin Resistance Syndrome: Mediators, pediatric insulin resistance, the polycystic ovary syndrome, and malignancy Diabetes Care, July 1, 2005; 28(7): 1821 - 1830. [Full Text] [PDF]

				D. Lu, H. Zhang, H. Koo, J. Tonra, P. Balderes, M. Prewett, E. Corcoran, V. Mangalampalli, R. Bassi, D. Anselma, et al. A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity J. Biol. Chem., May 20, 2005; 280(20): 19665 - 19672. [Abstract] [Full Text] [PDF]

				S. Miyamoto, M. Nakamura, K. Shitara, K. Nakamura, Y. Ohki, G. Ishii, M. Goya, K. Kodama, T. Sangai, H. Maeda, et al. Blockade of Paracrine Supply of Insulin-Like Growth Factors Using Neutralizing Antibodies Suppresses the Liver Metastasis of Human Colorectal Cancers Clin. Cancer Res., May 1, 2005; 11(9): 3494 - 3502. [Abstract] [Full Text] [PDF]

				J. D. Wu, A. Odman, L. M. Higgins, K. Haugk, R. Vessella, D. L. Ludwig, and S. R. Plymate In vivo Effects of the Human Type I Insulin-Like Growth Factor Receptor Antibody A12 on Androgen-Dependent and Androgen-Independent Xenograft Human Prostate Tumors Clin. Cancer Res., April 15, 2005; 11(8): 3065 - 3074. [Abstract] [Full Text] [PDF]

				N. Loizos, Y. Xu, J. Huber, M. Liu, D. Lu, B. Finnerty, R. Rolser, A. Malikzay, A. Persaud, E. Corcoran, et al. Targeting the platelet-derived growth factor receptor {alpha} with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target Mol. Cancer Ther., March 1, 2005; 4(3): 369 - 379. [Abstract] [Full Text] [PDF]

				B. D. Cohen, D. A. Baker, C. Soderstrom, G. Tkalcevic, A. M. Rossi, P. E. Miller, M. W. Tengowski, F. Wang, A. Gualberto, J. S. Beebe, et al. Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti-Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871 Clin. Cancer Res., March 1, 2005; 11(5): 2063 - 2073. [Abstract] [Full Text] [PDF]

				G. S. Warshamana-Greene, J. Litz, E. Buchdunger, C. Garcia-Echeverria, F. Hofmann, and G. W. Krystal The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy Clin. Cancer Res., February 15, 2005; 11(4): 1563 - 1571. [Abstract] [Full Text] [PDF]

				Y. H. Ibrahim and D. Yee Insulin-Like Growth Factor-I and Breast Cancer Therapy Clin. Cancer Res., January 15, 2005; 11(2): 944s - 950s. [Abstract] [Full Text] [PDF]

				R. Kooijman and A. Coppens Insulin-like growth factor-I stimulates IL-10 production in human T cells J. Leukoc. Biol., October 1, 2004; 76(4): 862 - 867. [Abstract] [Full Text] [PDF]

				G. Bocci, S. Man, S. K. Green, G. Francia, J. M. L. Ebos, J. M. du Manoir, A. Weinerman, U. Emmenegger, L. Ma, P. Thorpe, et al. Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies Cancer Res., September 15, 2004; 64(18): 6616 - 6625. [Abstract] [Full Text] [PDF]